vs
Esperion Therapeutics, Inc.（ESPR）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是COMSCORE, INC.的1.8倍（$168.4M vs $93.5M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -1.5%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.8%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
ESPR vs SCOR — 直观对比
营收规模更大
ESPR
是对方的1.8倍
$93.5M
营收增速更快
ESPR
高出145.3%
-1.5%
两年增速更快
ESPR
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $93.5M |
| 净利润 | — | $3.0M |
| 毛利率 | — | 41.0% |
| 营业利润率 | 50.6% | 7.0% |
| 净利率 | — | 3.2% |
| 营收同比 | 143.7% | -1.5% |
| 净利润同比 | — | -3.7% |
| 每股收益（稀释后） | $0.32 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRSCOR
| Q4 25 | $168.4M | $93.5M | ||
| Q3 25 | $87.3M | $88.9M | ||
| Q2 25 | $82.4M | $89.4M | ||
| Q1 25 | $65.0M | $85.7M | ||
| Q4 24 | $69.1M | $94.9M | ||
| Q3 24 | $51.6M | $88.5M | ||
| Q2 24 | $73.8M | $85.8M | ||
| Q1 24 | $137.7M | $86.8M |
净利润ESPRSCOR
| Q4 25 | — | $3.0M | ||
| Q3 25 | $-31.3M | $453.0K | ||
| Q2 25 | $-12.7M | $-9.5M | ||
| Q1 25 | $-40.5M | $-4.0M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | $-29.5M | $-60.6M | ||
| Q2 24 | $-61.9M | $-1.7M | ||
| Q1 24 | $61.0M | $-1.1M |
毛利率ESPRSCOR
| Q4 25 | — | 41.0% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 40.6% | ||
| Q1 25 | — | 39.6% | ||
| Q4 24 | — | 42.4% | ||
| Q3 24 | — | 41.2% | ||
| Q2 24 | — | 39.5% | ||
| Q1 24 | — | 42.3% |
营业利润率ESPRSCOR
| Q4 25 | 50.6% | 7.0% | ||
| Q3 25 | -11.4% | 1.9% | ||
| Q2 25 | 8.6% | -1.9% | ||
| Q1 25 | -34.0% | -2.4% | ||
| Q4 24 | -6.4% | 4.1% | ||
| Q3 24 | -31.0% | -67.4% | ||
| Q2 24 | 3.5% | -2.2% | ||
| Q1 24 | 52.5% | -2.2% |
净利率ESPRSCOR
| Q4 25 | — | 3.2% | ||
| Q3 25 | -35.9% | 0.5% | ||
| Q2 25 | -15.4% | -10.6% | ||
| Q1 25 | -62.2% | -4.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -57.2% | -68.5% | ||
| Q2 24 | -83.9% | -2.0% | ||
| Q1 24 | 44.3% | -1.2% |
每股收益（稀释后）ESPRSCOR
| Q4 25 | $0.32 | $9.50 | ||
| Q3 25 | $-0.16 | $-0.86 | ||
| Q2 25 | $-0.06 | $-2.73 | ||
| Q1 25 | $-0.21 | $-1.66 | ||
| Q4 24 | $-0.14 | $-0.47 | ||
| Q3 24 | $-0.15 | $-12.79 | ||
| Q2 24 | $-0.33 | $-1.19 | ||
| Q1 24 | $0.34 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $23.6M |
| 总债务越低越好 | — | $41.5M |
| 股东权益账面价值 | $-302.0M | $111.4M |
| 总资产 | $465.9M | $407.7M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ESPRSCOR
| Q4 25 | $167.9M | $23.6M | ||
| Q3 25 | $92.4M | $26.7M | ||
| Q2 25 | $86.1M | $26.0M | ||
| Q1 25 | $114.6M | $31.0M | ||
| Q4 24 | $144.8M | $29.9M | ||
| Q3 24 | $144.7M | $20.0M | ||
| Q2 24 | $189.3M | $14.7M | ||
| Q1 24 | $226.6M | $18.7M |
总债务ESPRSCOR
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ESPRSCOR
| Q4 25 | $-302.0M | $111.4M | ||
| Q3 25 | $-451.4M | $-26.3M | ||
| Q2 25 | $-433.5M | $-21.7M | ||
| Q1 25 | $-426.2M | $-13.5M | ||
| Q4 24 | $-388.7M | $-8.3M | ||
| Q3 24 | $-370.2M | $-2.7M | ||
| Q2 24 | $-344.2M | $45.8M | ||
| Q1 24 | $-294.3M | $51.4M |
总资产ESPRSCOR
| Q4 25 | $465.9M | $407.7M | ||
| Q3 25 | $364.0M | $406.9M | ||
| Q2 25 | $347.1M | $415.9M | ||
| Q1 25 | $324.0M | $421.5M | ||
| Q4 24 | $343.8M | $430.2M | ||
| Q3 24 | $314.1M | $412.5M | ||
| Q2 24 | $352.3M | $474.1M | ||
| Q1 24 | $373.1M | $477.7M |
负债/权益比ESPRSCOR
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | — | $2.9M |
| 自由现金流率自由现金流/营收 | — | 3.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.07× |
| 过去12个月自由现金流最近4个季度 | — | $21.8M |
8季度趋势，按日历期对齐
经营现金流ESPRSCOR
| Q4 25 | $45.2M | $3.2M | ||
| Q3 25 | $-4.3M | $9.5M | ||
| Q2 25 | $-31.4M | $932.0K | ||
| Q1 25 | $-22.6M | $9.1M | ||
| Q4 24 | $-35.0M | $-10.0M | ||
| Q3 24 | $-35.3M | $12.5M | ||
| Q2 24 | $-7.2M | $8.7M | ||
| Q1 24 | $53.8M | $6.9M |
自由现金流ESPRSCOR
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $9.4M | ||
| Q2 25 | — | $787.0K | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | $-35.5M | $12.4M | ||
| Q2 24 | $-7.3M | $8.5M | ||
| Q1 24 | $53.8M | $6.6M |
自由现金流率ESPRSCOR
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | -10.8% | ||
| Q3 24 | -68.7% | 14.0% | ||
| Q2 24 | -9.9% | 10.0% | ||
| Q1 24 | 39.0% | 7.6% |
资本支出强度ESPRSCOR
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.2% | ||
| Q1 24 | 0.1% | 0.3% |
现金转化率ESPRSCOR
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
